STOCK TITAN

ANI Pharmaceuticals to Discuss First Quarter 2024 Financial Results on May 10, 2024, at 8:30 a.m. ET

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
ANI Pharmaceuticals, Inc. announced its first quarter 2024 financial results discussion on May 10, 2024, at 8:30 a.m. ET. The conference call will be hosted by Nikhil Lalwani, President, and CEO, and Stephen P. Carey, CFO.
ANI Pharmaceuticals, Inc. ha annunciato la discussione sui risultati finanziari del primo trimestre del 2024 che si terrà il 10 maggio 2024, alle 8:30 a.m. ET. La conferenza sarà presieduta da Nikhil Lalwani, Presidente e CEO, e da Stephen P. Carey, CFO.
ANI Pharmaceuticals, Inc. anunció la discusión de los resultados financieros del primer trimestre de 2024 el 10 de mayo de 2024, a las 8:30 a.m. ET. La conferencia será dirigida por Nikhil Lalwani, Presidente y CEO, y Stephen P. Carey, CFO.
ANI Pharmaceuticals, Inc.는 2024년 5월 10일 오전 8시 30분 ET에 2024년 1분기 재무 결과에 대한 토론을 발표했습니다. 회의는 Nikhil Lalwani 사장 겸 CEO와 Stephen P. Carey CFO가 주관할 예정입니다.
ANI Pharmaceuticals, Inc. a annoncé la discussion de ses résultats financiers pour le premier trimestre de 2024 le 10 mai 2024 à 8h30 ET. La conférence sera animée par Nikhil Lalwani, Président et CEO, et par Stephen P. Carey, CFO.
ANI Pharmaceuticals, Inc. hat die Besprechung der Finanzergebnisse für das erste Quartal 2024 am 10. Mai 2024 um 8:30 Uhr ET angekündigt. Die Telefonkonferenz wird von Nikhil Lalwani, Präsident und CEO, und Stephen P. Carey, CFO, geleitet.
Positive
  • None.
Negative
  • None.

BAUDETTE, Minn., April 18, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its first quarter 2024 financial results on Friday, May 10, 2024, prior to the market open.

Nikhil Lalwani, President and Chief Executive Officer, and Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, will host a conference call to discuss the results as follows:

DateFriday, May 10, 2024
  
Time8:30 a.m. ET
  
Toll free (U.S.)800-274-8461
  
Conference ID4555224
  
Webcast (live and replay)www.anipharmaceuticals.com, under the “Investors” section
  

A replay of the conference call will be available within two hours of the call’s completion and will remain accessible for two weeks by dialing 800-938-2239 and entering access code 4555224.

About ANI
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company serving patients in need by developing, manufacturing, and marketing high-quality branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. The Company is focused on delivering sustainable growth by scaling up its Rare Disease business through its lead asset Purified Cortrophin® Gel, strengthening its Generics business with enhanced research and development capabilities, leveraging its U.S. based manufacturing footprint, and delivering innovation in Established Brands. For more information, please visit our website www.anipharmaceuticals.com.

Investor Relations Contact:
Lisa M. Wilson, In-Site Communications, Inc.
212-452-2793
lwilson@insitecony.com

SOURCE: ANI Pharmaceuticals, Inc.


FAQ

When will ANI Pharmaceuticals discuss its first quarter 2024 financial results?

ANI Pharmaceuticals will discuss its first quarter 2024 financial results on May 10, 2024.

Who will host the conference call to discuss the financial results?

The conference call will be hosted by Nikhil Lalwani, President, and CEO, and Stephen P. Carey, CFO.

Where can I access the live and replay webcast of the conference call?

You can access the live and replay webcast of the conference call on www.anipharmaceuticals.com under the 'Investors' section.

How long will the replay of the conference call be available?

The replay of the conference call will be available within two hours of the call's completion and will remain accessible for two weeks.

ANI Pharmaceuticals, Inc.

NASDAQ:ANIP

ANIP Rankings

ANIP Latest News

ANIP Stock Data

1.14B
17.27M
11.09%
100.07%
10.04%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
BAUDETTE